Company Overview
Company Name
VTV Therapeutics
Address
United States
Website
vtvtherapeutics.comPhone
(555) 555-5555Approx. Annual Revenue
$7.2M
Employees
40
Established
2015
Locations
2
About VTV Therapeutics
VTV Therapeutics is a clinical-stage biopharmaceutical company based in the United States. With approximately 11 employees, the company is focused on developing oral, small molecule drug candidates to treat type 1 diabetes and other chronic conditions. VTV's pipeline includes several drug candidates, including cadisegliatin, which is being investigated as a potential adjunctive therapy to insulin for type 1 diabetes.
Business Profile
Read from the VTV Therapeutics website on Oct 13, 2026. Hover an item to see the exact wording it came from.
About the website
- Website quality (AI-assessed)
- 8/10 · Current copyright notice 2026; Detailed clinical pipeline information
- Footer copyright year
- 2026
VTV Therapeutics locations
2 Google Business Profile listings.
| Location | Google category | Reviews | Status |
|---|---|---|---|
| VTV Therapeuticsprimary | — | — | — |
| 3980 Premier Dr #310, High Point, NC | — | 4.5 (2) | Claimed |
Biotech & Life Sciences Companies near CA
- Outset Medicaloutsetmedical.com
- Noema Pharmanoemapharma.com
- Topography Healthjointopo.com
- Apogee Therapeuticsapogeetherapeutics.com
- Science 37science37.com
- Acadia Pharmaceuticalsacadia-pharm.com
- AADI Bioscienceaadibio.com
- Fractyl Healthfractyl.com
- Eledon Pharmaceuticalseledon.com
- Candel Therapeuticscandeltx.com
Frequently Asked Questions about VTV Therapeutics
Categories
Technologies Used
;%20fill-rule:%20evenodd;%20}%20.cls-2%20{%20fill:%20none;%20}%20%3c/style%3e%3clinearGradient%20id='linear-gradient'%20x1='-1275.62'%20y1='432.1'%20x2='-1272.18'%20y2='427.35'%20gradientTransform='translate(30659%2010381.36)%20scale(24%20-24)'%20gradientUnits='userSpaceOnUse'%3e%3cstop%20offset='0'%20stop-color='%2325c5ff'/%3e%3cstop%20offset='.45'%20stop-color='%230048ff'/%3e%3cstop%20offset='1'%20stop-color='%23c500f3'/%3e%3c/linearGradient%3e%3c/defs%3e%3cpath%20class='cls-2'%20d='M0,0H150V150H0V0Z'/%3e%3cg%20id='Layer_2'%20data-name='Layer%202'%3e%3cg%20id='Layer_1-2'%20data-name='Layer%201-2'%3e%3cg%20id='Artboard'%3e%3cg%20id='userway_logo'%20data-name='userway%20logo'%3e%3cpath%20id='Combined-Shape'%20class='cls-1'%20d='M18.75,36.94c5.16-.03,9.36,4.13,9.39,9.28,0,.03,0,.07,0,.1h0v7.3h0v23.47c0,26.79,21.71,48.5,48.5,48.5s48.5-21.71,48.5-48.5h0v-23.99h0v-7.3c-.03-5.16,4.13-9.36,9.28-9.39,.03,0,.07,0,.1,0h4.69v40.68c0,34.56-28.02,62.58-62.58,62.58S14.06,111.66,14.06,77.1h0V36.94h4.69Zm2.09-22.42c16.1-.03,29.18,13,29.2,29.1,0,.03,0,.07,0,.1v33.38c0,14.69,11.91,26.6,26.6,26.6s26.6-11.91,26.6-26.6V43.72c-.03-16.1,13-29.18,29.1-29.2,.03,0,.07,0,.1,0h6.78v14.08h-6.78c-8.35,0-15.12,6.77-15.12,15.12v33.38c0,22.18-17.98,40.16-40.16,40.16h0c-22.28,.03-40.42-17.88-40.68-40.16V43.72c-.08-8.44-6.99-15.21-15.43-15.13-.07,0-.14,0-.21,0h-6.78V14.52h6.78Z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Social Profiles
Key Decision Makers
Elizabeth Keiley Executive Vice President, General Counsel
Ashley Johns Senior Vice President, Clinical Operations
Martin Lafontaine Chief Commercial Officer
Rich Nelson Executive Vice President, Chief Business Officer
Carmen Valcarce Executive Vice President, Chief Scientific Officer
Michael Tung Executive Vice President, Chief Financial Officer
Paul Sekhri Chairman, President, and Chief Executive Officer
Thomas Strack Executive Vice President, Chief Medical Officer
Jennifer Freeman Vice President Clinical Operations